Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
NCT02802423
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Triple Negative Breast Cancer
Interventions
DRUG:
BLEX 404 Oral Liquid
Sponsor
BioLite, Inc.